Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 9, 2021
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing dataAlasdair J Coles, Joanne L Jones, Patrick Vermersch, et al.Journal of the Neurological Sciences|March 25, 2018
Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from 23Na-MRIJames T Grist, Frank Riemer, Mary A McLean, et al.Annals of Clinical and Translational Neurology|September 18, 2022
Remyelination varies between and within lesions in multiple sclerosis following bexaroteneJ William L Brown, Ferran Prados, Daniel R Altmann, et al.Communications Biology|October 15, 2021
Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73Lorna B Jarvis, Daniel B Rainbow, Valerie Coppard, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 19, 2021
Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain InjuryEdward J Needham, Oda Stoevesandt, Eric P Thelin, et al.JCI Insight|August 18, 2017
Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2Marcin L Pekalski, Arcadio Rubio García, Ricardo C Ferreira, et al.Nature Immunology|February 19, 2020
Distinct microbial and immune niches of the human colonKylie R James, Tomas Gomes, Rasa Elmentaite, et al.JCI Insight|May 8, 2019
Keratinocyte growth factor impairs human thymic recovery from lymphopeniaAlasdair J Coles, Laura Azzopardi, Onajite Kousin-Ezewu, et al.The Lancet. Neurology|August 21, 2021
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a studyJ William L Brown, Nick G Cunniffe, Ferran Prados, et al.Cytotherapy|April 3, 2026
A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancerRebecca N Graham, Alice Davies, Monica L Mullin, et al.Pageof 5